• Startup Pulse
    altM raises $10.3 million in a Series A round led by Rainmatter by Zerodha and Mela Ventures, with Omnivore, Theia Ventures, Aureolis Ventures, Spectrum Impact and strategic angel investors participating. Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. EloElo Group raises $80 million in a Series C round led by Hornbill Capital and NBCUniversal, with MIT Investment Co. and existing investors participating. Peppermint Robotics raises ₹100 crore (approximately $10.5 million) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with Asiana Fund participating. Traversal raises $120 million in a Series B round at a $1 billion valuation, led by Kleiner Perkins, Redpoint and Khosla Ventures, with Sequoia Capital, Battery Ventures and Amex Ventures participating. GIVA raises over $100 million in a round led by Multiples Alternate Asset Management. The Croffle Guys raises ₹14 crore in a round led by V3 Ventures, with N.A.N Partners participating. Solgram raises over $1 million in a pre-seed round led by DSG Consumer Partners and Saama Capital, with Kapil Chopra participating. Sachin Tendulkar makes a strategic investment in Metasports Interactive, the company behind Hitwicket. The amount was not disclosed. Hyeglo Beauty raises ₹7 crore in a round led by Sauce, with Giga Capital, Consumer Collective, Reckitt's Arjun Purkayastha and The Patient Capital participating. altM raises $10.3 million in a Series A round led by Rainmatter by Zerodha and Mela Ventures, with Omnivore, Theia Ventures, Aureolis Ventures, Spectrum Impact and strategic angel investors participating. Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. EloElo Group raises $80 million in a Series C round led by Hornbill Capital and NBCUniversal, with MIT Investment Co. and existing investors participating. Peppermint Robotics raises ₹100 crore (approximately $10.5 million) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with Asiana Fund participating. Traversal raises $120 million in a Series B round at a $1 billion valuation, led by Kleiner Perkins, Redpoint and Khosla Ventures, with Sequoia Capital, Battery Ventures and Amex Ventures participating. GIVA raises over $100 million in a round led by Multiples Alternate Asset Management. The Croffle Guys raises ₹14 crore in a round led by V3 Ventures, with N.A.N Partners participating. Solgram raises over $1 million in a pre-seed round led by DSG Consumer Partners and Saama Capital, with Kapil Chopra participating. Sachin Tendulkar makes a strategic investment in Metasports Interactive, the company behind Hitwicket. The amount was not disclosed. Hyeglo Beauty raises ₹7 crore in a round led by Sauce, with Giga Capital, Consumer Collective, Reckitt's Arjun Purkayastha and The Patient Capital participating.
  • Ayurvedic Rasayana Therapy Improves Survival in Advanced Pancreatic Cancer

    Ayurvedic Rasayana therapy

    Pune: In a development that could redefine supportive oncology care, a Pune-based study on Ayurvedic Rasayana therapy has demonstrated improved survival outcomes and enhanced quality of life in patients with advanced pancreatic cancer.

    The findings on Ayurvedic Rasayana therapy were presented at the annual meeting of the American Association for Cancer Research in San Diego, USA, drawing significant attention from the global oncology community.

    The study, conducted by researchers at the Rasayu Cancer Clinic and led by Dr Yogesh Bendale, evaluated 17 patients diagnosed with advanced-stage pancreatic cancer who were ineligible for surgery, chemotherapy, or other conventional treatments.

    The research on Ayurvedic Rasayana therapy has also been published in the internationally reputed journal Cancer Research, which has an impact factor of 16.6.

    Also Read: Ministry of Ayush, DBT Launch Study on Ayurveda for Anti-Tuberculosis Treatment

    Pancreatic cancer is widely regarded as one of the most aggressive and difficult-to-treat malignancies, often detected at an advanced stage when therapeutic options are limited.

    In such cases, average survival typically ranges between three to six months. However, the Pune study found that patients undergoing Ayurvedic Rasayana therapy recorded a median survival of 10 to 11 months, indicating a notable improvement.

    Beyond survival, the study highlighted meaningful improvements in patients’ quality of life through Ayurvedic Rasayana therapy. Patients reported better appetite, reduced fatigue, and improved daily functioning.

    Additionally, nearly 12 per cent of cases showed a reduction in tumour size—an outcome considered significant given the advanced stage of the disease.

    According to Dr Yogesh Bendale, Ayurvedic Rasayana therapy works by strengthening the body’s inherent resilience and ability to combat disease. “In advanced pancreatic cancer, where treatment options are often exhausted, Rasayana therapy offers patients a chance to live longer with dignity and improved well-being,” he stated.

    The findings also reinforce the growing importance of integrative oncology, a treatment approach that combines modern Western medicine with complementary therapies such as Ayurveda.

    Ayurvedic Rasayana Therapy: Supportive Role in Integrated Model, Especially for Patients with Limited Treatment Alternatives

    Also Read: Nihon Kohden Launches Advanced Life Scope E7 Monitoring Platform for Indian Hospitals

    Researchers involved in the study include Dr Poonam Birari-Gavande, Dr Priyanka Shirole, and Dr Avinash Kadam, who contributed to evaluating the clinical outcomes of Ayurvedic Rasayana therapy in advanced cancer care.

    With global platforms like the American Association for Cancer Research recognising such research, the Pune study is expected to contribute to a broader reassessment of traditional medicine systems in oncology.

    The findings indicate that Ayurvedic Rasayana therapy may emerge as a valuable supportive care option, particularly for patients facing limited conventional treatment pathways.

    Author

    • Salil Urunkar

      Salil Urunkar is a senior journalist and the editorial mind behind Sahyadri Startups. With years of experience covering Pune’s entrepreneurial rise, he’s passionate about telling the real stories of founders, disruptors, and game-changers.

    Back to top